Physician profile
Gervacio Daniel Diaz
NPI 1700835451
$7,094.51
in general payments reported to CMS, 2019-2025
36 companies · $836 in 2025
The $836 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $647 · 2021: $1,159 · 2022: $1,559 · 2023: $939 · 2024: $1,005 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,753 · Education: $26.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.35 |
| Education | $26.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,594.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $681.77 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $467.35 | 2019-2025 | Repatha, Evenity, Otezla |
| E.R. Squibb & Sons, L.L.C. | $465.28 | 2019-2024 | Eliquis |
| Lilly USA, LLC | $450.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $414.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $382.95 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.83 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $317.60 | 2019-2023 | Xarelto |
| Sumitomo Pharma America, INC. | $247.32 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $193.23 | 2019-2023 | |
| Abbvie INC. | $156.50 | 2021-2023 | Vraylar |
| Biocryst US Sales Co., LLC | $148.32 | 2021-2025 | Orladeyo |
| Csl Behring | $140.66 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $136.37 | 2019-2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gervacio Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.